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Trichomonas vaginalis (TV) infection is the most prevalent curable sexually transmitted infection in the United
States and worldwide. Most TV infections are asymptomatic, and the accurate diagnosis of this infection has
been limited by lack of sufficiently sensitive and specific diagnostic tests, particularly for men. To provide
updates for the 2010 Centers for Disease Control and Prevention’s Sexually Transmitted Diseases Treatment
Guidelines, a PubMed search was conducted of all TV literature published from 9 January 2004 through
24 September 2008. Approximately 175 pertinent abstracts and articles were reviewed and discussed with
national experts. This article describes advances in TV diagnostics which have led to an improved
understanding of the epidemiology of this pathogen, as well as potential biologic and epidemiological
interactions between TV and human immunodeficiency virus (HIV). New data on treatment outcomes,
metronidazole-resistant TV, management of nitroimidazole-allergic patients, frequency of recurrent TV
infection following treatment, and screening considerations for TV in certain populations are also presented.
Trichomonas vaginalis (TV) infection is the most prev-
alent curable sexually transmitted infection (STI) in the
United States and in the world [1]. In the United States,
a recent population-based study demonstrated an
overall prevalence of 3.1% (95% confidence interval
[CI], 2.3%–4.3%) among women aged 14–49 years, with
rates as high as 13.3% (95% CI, 10.0%–17.7%) among
black women in the general population. Almost 20% of
black women aged 40–49 years were infected in this
study and symptoms did not predict TV infection [2].
Another recent study found a TV prevalence of 6.2%
(95% CI, 4.4%–8.1%) among Baltimore residents aged
15–35 years (Susan Rogers, Research Triangle Institute,
personal communication, February 2009). TV preva-
lence was 5-fold higher among women than among men
(10.1% vs 2.0%, respectively; prevalence ratio, 5.1%;
95% CI, 2.0%–13.0%), and 1 in 7 black women were
found to be infected (estimated prevalence, 14.2%; 95%
CI, 10.3%–19.3%). Among women and men attending
US sexually transmitted disease (STD) clinics, TV
prevalence is generally higher, with a range of 13%–34%
[3] for women and 3%–17% for men [4–8]. Tricho-
moniasis is also frequently diagnosed among women
infected with human immunodeficiency virus (HIV),
with reported prevalences of 6.1%–52.6% [9–17]. This
article outlines new developments since the 2006 Centers
for Disease Control and Prevention (CDC) STD Treat-
ment Guidelines, including advances in TV diagnostics,
new data on treatment outcomes, metronidazole-
resistant TV, management of nitroimidazole-allergic
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patients, frequency of recurrent TV infection following treat-
ment, TV infection in HIV-infected women, potential bi-
ological interactions between TV and HIV, and screening
considerations for TV in certain populations.
METHODS
A PubMed (US National Library of Medicine and the National
Institutes of Health) search was conducted of all literature
published from 9 January 2004 through 24 September 2008 using
the search terms ‘‘trichomonas’’ (520 articles), ‘‘Trichomonas
vaginalis’’ (398 articles), ‘‘trichomoniasis’’ (485 articles), and
‘‘trich’’ (21 articles), without limitations except human studies.
In addition, the National Center for Biotechnology Information
sent notifications of all publications with the keyword ‘‘tricho-
moniasis,’’ subsequent to the dates of the literature review.
Abstracts in hard copy and online were reviewed from relevant
conferences using the search terms above. All abstracts were
reviewed and pertinent articles were read, 175 documents in
total. After each article was read, a determination was made as
to whether it provided data relevant to the CDC STD Treat-
ment Guidelines. Pertinent articles were summarized and en-
tered into a table of evidence that was used to inform the key
questions addressed in the guidelines document. In addition,
6 subject matter experts were contacted to add their expertise to
the literature review.
RESULTS
Improved Trichomonas vaginalis Diagnostics
Greater knowledge about TV epidemiology reflects improved
TV diagnostics, although new detection methods have yet to be
incorporated into most clinical settings. To date, the most
common clinical method for TV diagnosis in women remains
microscopic evaluation of vaginal wet preparations due to its
low cost and simplicity. Unfortunately, the sensitivity of wet
preparation for TV diagnosis is poor at 60%–70% and can de-
crease to 20% if microscopic evaluation is delayed by as few as
10 minutes [18]; such delays are not uncommon in busy clinical
settings. Therefore, to maximize the performance of the wet
preparation for TV diagnosis, slides of vaginal fluid must be
examined immediately following specimen collection.
Culture, using a variety of liquid and semisolid media, re-
mains the gold standard for diagnosis of trichomoniasis and is
available in pouches containing modified Diamond medium
[19–22]. In women, vaginal secretions should be cultured for
TV, as urine culture is less sensitive [23, 24]. Self-collected
vaginal swabs are as sensitive as clinician-obtained specimens
for TV culture [25]. Once inoculated, cultures are incubated and
examined daily for 3–5 days by use of microscopy. If the wet
mount is negative, then a combined approach of microscopy
followed by culture can be useful [25, 26]. Papanicolaou tests
can also detect TV in women, but their sensitivity for TV di-
agnosis is poor. TV detected by Papanicolaou test should be
treated; confirmatory testing is unnecessary [27].
Newer Food and Drug Administration (FDA)–cleared point-
of-care tests for trichomoniasis in women include the OSOM
Trichomonas rapid antigen test (Genzyme Diagnostics), an
antigen-detection test that uses immunochromatographic cap-
illary flow dipstick technology, and the Affirm VP III (Becton
Dickenson), a nucleic acid probe-hybridization test that eval-
uates TV, Gardnerella vaginalis, and Candida albicans. These
tests are performed on vaginal secretions and provide superior
sensitivity (.83%) and specificity (.97%) over wet mount
examination for trichomoniasis [28–30]. The OSOM Tricho-
monas rapid antigen test results are available in 10 minutes,
and the Affirm VP III results are available within 45 minutes.
Although both of these tests are more sensitive than vaginal wet
preparations, false positives may occur, especially in populations
with low TV prevalence in which the positive predictive value of
the test is low. The Affirm VP III and OSOMTrichomonas rapid
antigen tests offer the potential to improve TV diagnosis, es-
pecially in settings where a microscope is not immediately
available or in settings where point-of-care testing offers sub-
stantial benefit for improved treatment.
In men, wet preparation lacks sensitivity, and neither the
OSOM test nor the Affirm VP III test is available for use with
male urethral specimens. Culture may be performed using a
urine sample, a urethral swab sample, or a semen sample. In
men, multiple specimens can be used to inoculate a single cul-
ture to improve yield. However, even under optimal conditions,
culture is not a sensitive diagnostic method in men.
Highly sensitive nucleic acid amplification TV testing is now
commercially available. APTIMA TV analyte-specific reagents
(ASRs; manufactured by Gen-Probe) detect TV RNA by
transcription-mediated amplification using the same instru-
mentation platforms available for the FDA-cleared APTIMA
Combo2 assay for gonorrhea and chlamydial infection. FDA
clearance for TV testing of endocervical swabs, vaginal swabs,
urine samples, and specimens collected in PreservCyt solution
from both asymptomatic and symptomatic women was granted
in April 2011. Although Gen-Probe TV ASRs can be used to test
urethral swabs and urine samples from men, FDA clearance has
not been received for male specimen types. Therefore, the sale,
distribution, and use of ASRs for male specimens are covered
under 21 C.F.R. PART 809.30 pertaining to in vitro diagnostic
products for human use. Published validation studies from
individual laboratories report TV ASR sensitivities of 74%–
98% and specificities of 87%–98%, depending on the specimen
evaluated and the reference standard used [31–33] (Table 1).
In addition, although TV is often considered by clinicians
to be strictly a vaginal pathogen, TV can be detected from
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Table 1. Selected Studies Demonstrating Performance Characteristics of Transcription-Mediated Amplification and Polymerase Chain
Reaction for Detection of Trichomonas vaginalis Genital Tract Infection
Citation , study population, specimen site, diagnostic test, details Sensitivity, % (95% CI) Specificity, % (95% CI)
Van Der Pol 2006a
STD clinic
Vaginal (N 5 174)
WP 61.5 (46.2–76.8) 100
PCR
TVA 48.7 (33.0–64.4) 100 (100)
TVK 79.5 (66.8–92.2) 97.8 (95.3–100.0)
Male urine (N 5 503)
CX 56.0 (36.5–75.5) 100
PCR
TVK 96.0 (88.3–100.0) 99.2 (98.4–100.0)
b -Tubulin 92.0 (81.4–100.0) 99.4 (98.7–100.0)
Hardickb,c 2006
STD clinic
Vaginal (N 5 321)
TMA 98.2 98.1
Male urine (N 5 290)
TMA 100 100
Huppert 2007d
Teen health center and emergency department
Vaginal (N 5 330)
WP 64.6 (49.5–77.8) NA
CX 95.8 (85.7–99.5) NA
Rapid antigene 89.6 (77.3–96.5) 97.5 (95.0–99.0)
TMA 97.9 (88.9–100.0) 95.3 (92.3–97.5)
Nye 2009f
STD clinic
Vaginal, endocervical, female urine (N 5 296)
WP 54.6 (43.6–65.1) 100 (97.7–100)
CX 75.0 (64.4–83.4) 100 (97.7–100)
PCR vaginal 83.0 (73.1–89.8) 100 (97.7–100)
PCR endocervical 80.9 (70.6–88.0) 100 (97.7–100)
PCR urine 76.1 (65.6–84.3) 100 (97.7–100)
TMA vaginal 96.6 (89.7–99.1) 100 (97.7–100)
TMA endocervical 89.8 (81.0–94.9) 100 (97.7–100)
TMA urine 87.5 (78.3–93.3) 100 (97.7–100)
Urethral, male urine (N 5 298)
CX 28.6 (16.2–44.8) 100 (98.2–100)
PCR urethral 54.8 (38.8–69.8) 100 (98.2–100)
PCR urine 47.6 (32.3–63.4) 100 (98.2–100)
TMA urethral 95.2 (82.6–99.2) 96.5 (93.2–98.3)
TMA urine 73.8 (57.7–85.6) 98.4 (95.8–99.5)
APTIMA TV analyte-specific reagents are manufactured by Gen-Probe. Polymerase chain reaction (PCR) assays are commercially available and manufactured by
Roche Diagnostic and modified to detect T. vaginalis.
Abbreviations: CI, confidence interval; CX, T. vaginalis culture; NA, not available; STD, sexually transmitted disease; TMA, transcription-mediated amplification;
WP, wet preparation.
a Infection is defined by positive wet mount or a sample positive by both PCR assays for women and by positive culture or a urine sample positive by both PCR
assays for men.
b Infection is defined by 2 positive amplified results from RMA BTUB FRET PCR or alternative PCR using primer set TVK3 and TVK4 or wet preparation result.
c Resolved sensitivity and specificity presented; no 95% CI presented.
d Performance characteristics utilizing the traditional reference standard are presentedwhere infection is defined by the presence of a positivewetmount or culture result.
e OSOM Trichomonas rapid antigen test.
f Data frommolecular resolved algorithm presented where infection was defined as any positive test result: culture, wet preparation, PCR, or TMA confirmed by an
alternative TMA research-use only assay.
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endocervical specimens with nucleic acid amplification tests
(NAATs) at comparable frequencies to those of vaginal speci-
mens. Therefore, testing for Chlamydia trachomatis, Neisseria
gonorrhoeae, and TV from the same specimen may provide
comparable sensitivity and specificity to those of individually
collected specimens while simplifying specimen collection in
those patients for whom testing is indicated [34, 35]. In addition,
a commercially available, FDA-cleared polymerase chain reaction
(PCR) assay for detection of gonorrhea and chlamydial infection
(Amplicor, manufactured by Roche Diagnostic) has been mod-
ified to detect TV DNA in vaginal or endocervical swabs and in
urine samples from women and men with sensitivities of 88%–
97% and specificities of 98%–99%, depending on the specimen
and reference standard [36]. Other PCR detection assays may be
available from laboratories that have developed and validated
these tests, but none is FDA-cleared or commercially available.
Therefore, APTIMA GenProbe Combo TV ASRs are now
available as an FDA-cleared test for several types of specimens in
women, but it has only been studied (not FDA-cleared) for urine
samples and urethral swabs in males. Other NAAT-based TV
tests are being evaluated; peer-reviewed studies demonstrate that
these tests provide optimal sensitivity and acceptable specificity
for diagnosis in varied specimens from both men and women
(Table 1). Laboratories that currently use the Gen-Probe AP-
TIMA Combo2 test for N. gonorrhoeae and C. trachomatis can
add the TV ASRs to their testing menus if these tests are clini-
cally applicable. Laboratories that use the Roche Amplicor assay
can add the modified TV PCR assay as needed.
Treatment of Trichomonas vaginalis Infection
Tinidazole, a 5-nitroimidazole, was introduced for treatment of
TV infections in 1969 and has been available outside the United
States for several decades. The FDA approved tinidazole for
trichomoniasis in 2004. Tinidazole is available under the trade
name of Tindamax in 250-milligram and 500-milligram form.
Tinidazole has a half-life of approximately 12.5 hours compared
with 7.3 hours for metronidazole [37]. Serum and genitourinary
tract tinidazole levels have been reported to be 1.4–2-fold higher
than metronidazole levels [38, 39].
Randomized controlled trials comparing a 2-g single oral dose
of tinidazole to a 2-gram single oral dose of metronidazole or
short-course metronidazole have demonstrated tinidazole par-
asitologic cure rates of 86–100% in women [40–46]. In these
trials, tinidazole efficacy equaled or proved superior to that of
metronidazole. A Cochrane database meta-analysis of 8 ran-
domized trials, all but one comparing short-course therapy for
TV using tinidazole and metronidazole, included one trial
published in Norwegian and one trial that compared ornidazole
with metronidazole [47]. The latter trial was not included in the
comparisons of parasitological cure, clinical cure, or adverse
effects. Metronidazole users had a significantly higher
parasitological failure rate (10.9% [32 of 293 individuals] vs
3.3% [10 of 302 individuals]; P 5 .00055), a higher clinical
failure rate (14.8% [31 of 210 individuals] vs 3.7% [8 of 216
individuals]; P5 .00034), and more frequently reported adverse
effects (47.3% [107 of 226 individuals] vs 28.9% [67 of 232]
individuals; P 5 .00001) compared with individuals receiving
tinidazole [47]. The largest study of tinidazole treatment
(2-gram single oral dose) was a multicenter open-label trial
that documented parasitologic cure in 818 (95%) of 859 women
by wet preparation. Therefore, a 2-gram single oral dose of
tinidazole appears to be as effective as or superior to a 2-gram
single oral dose of metronidazole, and both of these drugs are
recommended for the treatment of TV infection.
There are few published data available on the efficacy of met-
ronidazole or tinidazole inmen. In one study, all of 39 TV-infected
men were cured after treatment with a 1-gram single oral dose of
tinidazole [48]. Wallin and colleagues reported on 11 men treated
with a 1.6-gram or 2-gram single oral dose of tinidazole, including
10 men who were cured on follow-up evaluation [49]. Massa and
colleagues reported an 83% cure rate for 2-gram single oral dose
tinidazole therapy in a cohort of 30 men [50]. Despite the paucity
of data derived from clinical trials, both metronidazole and tini-
dazole are recommended treatment regimens in men.
The initial treatment regimen for nongonococcal urethritis
(NGU) in men does not currently include a nitroimidazole for
TV infection. A recent randomized controlled trial for treatment
of NGU in men has found that the addition of tinidazole to the
treatment regimen does not result in higher cure rates but does
effectively eradicate trichomonas [51]. Prior studies have shown
that urethritis on Gram stain does not appear to be associated
with PCR-diagnosed TV infection in men [6, 52]. Data from
a trial conducted in Malawi found that adding metronidazole to
an empiric antibiotic regimen for urethritis did not improve
symptom resolution among men with TV infection who re-
turned for follow-up, although TV infection was cleared in these
men [53]. These data suggest that a nitroimidazole should not
be added to recommended first-line empirical NGU therapies
but should be considered as part of second-line therapy if
symptoms or signs of urethritis persist after initial treatment.
Treatment of Metronidazole-resistant Trichomonas vaginalis
Infection
Clinical failures with metronidazole have been reported since
1962. Current recommendations are to treat women in whom
initial therapy fails with either single-dose tinidazole therapy or
500 milligrams of metronidazole twice a day for 7 days. There is
minimal new data on the most appropriate management of
women in whom initial therapy with metronidazole fails. Sau-
rina and colleagues found low-level metronidazole resistance
in 3 (2.5%) of 118 TV isolates after treatment failure with
single-dose metronidazole. Treatment with 500 milligrams of
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metronidazole twice a day for 7 days resulted in cure in 2 of 3
women [54]. Schmid and colleages found low-level metroni-
dazole resistance in 2.4% of 82 isolates [55]. Follow-up was
available in only 1 of the 2 cases identified, and that patient was
cured after a single 2-gram dose of metronidazole.
In vitro data support the likelihood that tinidazole will be
effective following unsuccessful metronidazole therapy [56].
An evaluation of 104 clinical TV isolates from patients in whom
metronidazole treatment failed found that the mean aerobic
minimum lethal concentration (MLC) for tinidazole was
1014.9 lM compared with 2618 lM for metronidazole. Sixty
percent of isolates had a lower MLC to tinidazole than to met-
ronidazole. In addition, serum and genitourinary tract drug
levels of tinidazole are 1.5–2-fold higher than those of metro-
nidazole in men receiving 500 milligrams three times a day
(TID) a day of each medication [39]. Similarly, serum and
genitourinary tract drug levels of tinidazole are 1.4–1.8-fold
higher than of those of metronidazole in women receiving
400 milligrams of metronidazole TID or 500 milligrams of
tinidazole twice a day [38]. Tinidazole as a 2-gram single oral dose
proved effective in a limited number of cases with documented
TV treatment failure after divided-dose metronidazole therapy
of unspecified length (2 of 2 individuals cured) and standard
7-day metronidazole therapy (13 of 14 individuals cured) [40, 44].
Although the incidence of high-level metronidazole resistance
appears to be low, several case series published since 2000 docu-
ment cases of metronidazole treatment failure, with the largest
series including 24 cases [57]. Several of these reports documented
response to oral and/or intravaginal tinidazole with dosing regi-
mens ranging from 2 grams of tinidazole orally once a day for
2 days [58] to 1 gram of tinidazole orally TID with 500 milligrams
intravaginally TID for 14 days [57, 58]. In patients with clinical
failure following metronidazole and tinidazole at a total daily dose
of 2 grams orally plus a total dose of 1 g intravaginally or at a total
dose of 3 grams orally plus a total dose of 1.5 grams intravaginally
resulted in parasitologic cure for 30 of 34 patients reported
(Presutti laboratories compassionate availability program).
For women who have persistent trichomoniasis following
a 2-gram single dose of metronidazole, in whom treatment
failure is suspected and reinfection has been excluded, the cur-
rent recommendation is to treat with 500 milligrams of met-
ronidazole orally twice daily for 7 days. For patients failing this
regimen, clinicians should consider treatment with tinidazole or
metronidazole at 2 grams orally for 5 days. If these therapies are
not effective, further management should be discussed with
a specialist. The consultation should ideally include de-
termination of the susceptibility of TV to metronidazole and
tinidazole. Paromomycin, povidone-iodine, furazolidone, and
nonxynol-9 are topically applied agents that have anecdotal
reports of success although toxicity is high; a 40%–58% success
rate can be expected with these topical agents [57, 59, 60].
Although there are no data to guide treatment of the male
partners of women with treatment failure, the male partner should
be evaluated and treated with 500 milligrams of metronidazole
orally twice a day for 7 days or 2 grams of tinidazole orally in
a single dose. Single-dose metronidazole therapy should be avoi-
ded in the male partners of women with TV treatment failure.
Patients Allergic to 5-Nitroimidazoles
Few individuals have serious adverse reactions, including ana-
phylaxis, to 5-nitroimidazoles. Urticarial adverse reactions do not
always recur if therapy is repeated [61]. More severe, anaphylactic-
type reactions occur, but it is not known whether urticarial re-
actions predict subsequent anaphylaxis. Recently, Helms et al [59]
reported data collected from clinicians who consulted the CDC
on 59 patients with suspected hypersensitivity to metronidazole.
The most common reactions were urticaria (47%) and facial
edema (11%), based on patient history. Only 41 (69%) of 59
patients were treated following consultation, including 26 patients
treated with alternative regimens and 15 women who underwent
metronidazole desensitization that utilized either the oral (8
women) or the intravenous (7 women) published desensitization
regimen [59]. All patients who underwent desensitization and
were treated with metronidazole had their infections eradicated.
One woman who received the oral desensitization regimen ex-
perienced a pruritic rash on the final day that resolved with ste-
roids, and 1 women who received the intravenous desensitization
regimen experienced mild urticaria and pruritis 45 minutes after
the final 2-gram dose that was managed with diphenhydramine.
Alternative treatment regimens were used for 17 study subjects
with a cure rate of only 29.4% (5 of 17 subjects).
These observations suggest that severe reactions do not always
occur with subsequent metronidazole doses. However, there is
no proven way to determine who will react to re-exposure. It
appears that the best approach is to avoid nitroimidazoles in
patients with a history of prior allergic reactions, and that po-
tential alternative therapies have low success rates for tricho-
moniasis. For patients with adverse reactions to metronidazole
or tinidazole who require 5-nitroimidazole therapy, consultation
with an allergist or immunologist and, likely, desensitization are
recommended.
Trichomonas vaginalis Infection in HIV-infected Women
Despite the high prevalence of trichomoniasis demonstrated in
HIV-infected women (6.1%–33% tested using wet preparation
and/or culture and up to 52.6% tested with nucleic acid am-
plification) [10, 11, 13–15, 17], there are few data available to
guide TV infection management in this population. Kissinger
et al [62] found that TV infections were detected in 18.3% of
HIV-positive women at 1 month after treatment. There was no
difference in the proportion of cases determined to be due to
treatment failure between HIV-infected women (10%) and
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HIV-negative women (7.3%; P 5 .44). Moodley et al [14] also
found that HIV status did not influence TV infection cure rates
among symptomatic women treated with 2 grams of metroni-
dazole. Moodley et al [63] reported a significant 1.9-fold
increased risk of pelvic inflammatory disease in TV-positive
HIV-infected women in a cross-sectional study. The association
remained statistically significant regardless of whether tricho-
moniasis occurred as a single infection (relative risk, 3.4; 95% CI,
1.1–11.1) or in combination withN. gonorrhoeae, C. trachomatis,
or bacterial vaginosis (relative risk, 2.1 95%, CI 1.2–3.6); how-
ever, there was no information on treatment outcomes from this
study.
The standard treatment recommendations for trichomoniasis
have been based on studies that were conducted in HIV-negative
persons. However, a recent randomized clinical trial demon-
strated that a 2-gram single oral dose of metronidazole was not
as effective as 500 milligrams of metronidazole twice daily for
7 days for trichomoniasis among HIV-infected women [64].
Women in the 7-day arm had lower repeat TV infection rates at
test of cure (6–12 days after treatment completion; 8.5% [11 of
130 women] vs 16.8% [21 of 125 women]) and at 3 months
(11% [8 of 73 women] vs 24.1% [19 of 79 women]). Therefore,
a multidose treatment regimen for TV infection may be con-
sidered in HIV-infected women.
Potential Trichomonas vaginalis-HIV Interactions
The plausible biological synergy between TV and HIV has
been investigated in several studies (Table 2). Price et al [65]
demonstrated increased seminal HIV RNA levels in HIV-
positive men with TV urethral infections in Malawi. Mostad
et al [15] found no significant increases in HIV-infected cells
from cervical and vaginal secretions. In 2001, Wang and
colleagues noted a 4.23 decrease in mean HIV RNA genital
shedding (log 3.67 to log 3.05; P, .001) among HIV-infected
women after treatment of TV infection [66]. Kissinger et al
[67] showed that TV treatment reduced vaginal HIV shedding
over a 1–3-month period and that HIV-infected women with
TV infection had higher prevalence of HIV RNA in vaginal
secretions than did those without TV infection. Multiple re-
ports support the epidemiological association between HIV
and trichomoniasis. In a prospective cohort study, Laga and
colleagues found that TV infection was associated with a 1.7-
fold increased risk of HIV acquisition [68]. This finding was
supported in another cohort study in which McClelland et al
[12] demonstrated that TV infection was associated with
a significant 1.5-fold increased risk of HIV infection. A nested
case-control study of women by Van der Pol et al [69] also
found an association between TV infection and incident HIV
infection in multivariate analysis using wet mount (adjusted
odds ratio, 5.10) and PCR (adjusted odds ratio 2.74) for TV
detection.
Periodic screening of those at high risk of TV infection and
prompt treatment of TV infection is recommended for HIV-
positive women [70] on the basis of the high prevalence of
TV infection, the benefit of TV treatment in reducing vaginal
HIV shedding, and the potential to decrease upper genital tract
infections. Clinicians should consider screening for TV by wet
mount, culture, or a NAAT-based test for HIV-infected women
at the initial clinic visit, at least annually for sexually active in-
dividuals, and more often (ie, at 3–6-month intervals) for
asymptomatic persons at higher risk as suggested by current
guidelines [70]. If TV infection is identified in HIV-positive
women, then amultidose treatment regimen should be considered.
Rationale for Trichomonas vaginalis Screening in At-Risk
Populations
Because of the high prevalence of trichomoniasis in clinical and
nonclinical settings, testing for TV should be performed for
women seeking care for vaginal discharge. However, although
no study has adequately assessed screening for TV among
asymptomatic patients at STD clinics, including the optimal
frequency or cost-benefit of screening, epidemiological data do
suggest that TV infection is highly prevalent (3.1% among
women aged 14–49 years, with a rate as high as 13.3% among
black women in one national population-based study [2]) and
frequently asymptomatic (Susan Rogers, Research Triangle In-
stitute, personal communication, February 2009). For instance,
Rogers and colleagues found that 76% of the respondents di-
agnosed with TV infection in their probability-based sample of
Baltimore adolescents and young adults denied discharge and/or
dysuria within the past 3 months (Susan Rogers, Research Tri-
angle Institute, personal communication, February 2009), and the
larger population-based study performed by Sutton and col-
leagues found no significant differences in reported symptoms
between women with and those without TV infection [2]. In
addition, several studies have demonstrated that women with
other STIs, including gonorrhea and chlamydial infection, have
increased risk of TV coinfections and share common risk factors
[2, 71]. Additionally, studies have found an association between
TV infection and complications including preterm birth [72] and
pelvic inflammatory disease [63], and, as documented above,
there are potential interactions between TV and HIV infection
[12, 65–69]. As such, screening for TVmay be considered in those
women at high risk of infection (women with new or multiple
partners, history of STD, exchange of sex for payment, or injection
drug use), although further research to address the optimal fre-
quency and the cost-benefit of screening is certainly warranted.
Trichomonas vaginalis Persistence and Recurrence Following
Treatment
Kissinger et al [62] provided data from HIV-positive and
HIV-negative women suggesting that evaluation of organism
eradication for TV infection warrants consideration. Among
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Table 2. Selected Studies Examining Interaction Between Trichomonas vaginalis Infection and Human HIV Infection in Women
Study type citation Study design
Study population type and
setting Exposure and/or intervention Outcome measures Reported findings
Impact of TV infection
on HIV shedding in
the genital tract
Mostad 1997 Cross-sectional study
(N 5 318)
HIV-positive women at STD
clinic in Mombasa, Kenya
Interview, blood sample,
testing for BV (Gram stain),
CA, NG, CT, TV; vaginal and
endocervical swabs for HIV-1
DNA PCR of gag gene
HIV-1 shedding from
vagina and cervix
Mean age, 28 years; 70% were
CSWs, 9% had TV infection,
56% had BV, 13% had active
syphilis, 8% had NG infection,
and 4% had CT infection; mean
CD4 cell count, 451 cells/lL;
51% of women had
endocervical HIV shedding;
endocervical shedding more
likely with contraceptive use,
lower CD4 cell count, or NG
infection; vaginal shedding
seen in 14% of women and
more likely with lower CD4
cell count and candidal
infection; TV not associated
with vaginal shedding
Wang 2001 Longitudinal cohort
(N 5 203) with 242
vaginitis episodes
Excluded women with
evidence of cervicitis or GUD
Inclusion of women with BV
at initial or follow-up visit in
women with CA or TV treatment;
measurement of qualitative
HIV DNA and quantitative
vaginal HIV RNA levels
Effect of treatment of
vaginitis on HIV DNA
and RNA levels
27% of women had CD4 cell
count of ,200 cells/lL; TV
analyzed in 67 women
(6 missing swabs and 6 invalid
RNA results); 4.23 decrease
in mean HIV RNA level
(decrease from log 3.67
copies/mL to 3.05 copies/mL;
P , .001) but no significant
change in HIV DNA level with
treatment; adjusting for BV






















Study type citation Study design
Study population type and
setting Exposure and/or intervention Outcome measures Reported findings
Kissinger 2009 Prospective cohort with
matched controls on
selected confounders
(N 5 58 TV-positive
women successfully
treated with at least 1
follow-up; N 5 92
TV-negative controls);
GEEs used for repeat
measures
HIV-positive women attending
HIV outpatient program in
New Orleans, Louisiana
HIV-positive women $18 years old
scheduled to undergo
gynecological examination with
at least 1 follow-up visit enrolled;
women who tested positive by
wet mount or TV culture
performed at enrollment and
tested negative on at least 1
follow-up visit matched on ART
status and date of enrollment to
women testing negative at all
time points who returned for





0, 1, and 3 months;
accounted for phase
of menstrual cycle
Most women were black (81.3%);
median age, 37 years; median
CD4 cell count, 410 cells/lL
(range, 6–1823 cells/ll); median
plasma HIV-1 RNA level among
those with detectable virus
(n 5 120), 17,001 copies/mL
(range, 51–818,575 copies/mL);
median viral load of those
shedding vaginally (N 5 39),
553 copies/mL (range, 52–89,
300 copies/mL); TV-positive
women had higher prevalence of
detectable HIV-1 RNA in vaginal
secretions at baseline (36.2% vs
19.6%; P 5 .02) which remained
at 1 month (34.6% vs 14.1%;
P 5 .01) and then diminished
at 3 months (18.4% vs 12.2%;
P 5 .91); after adjusting for
ART (yes or no) and accounting
for repeat measures, women
successfully treated for TV
infection less likely to shed
virus at visits 2 and 3, compared
with visit 1, but TV-negative
women equally likely to be
shedding at all visits; no effect of
TV treatment on plasma viral load
Impact of TV on HIV
acquisition
McClelland 2007 Prospective study
(N 5 1335)
Open cohort study of FSWs




testing for HIV and STIs at
enrollment and monthly; women
with signs or symptoms of STI
syndromically managed at visit
and asked to return in 1 week for
follow-up test results; TV
diagnosed by wet preparation;
HIV-negative women with




risk of HIV-1 acquisition
in study population
Median age, 26 years; mean
duration of prostitution, 1 year;
at enrollment, 6% of women
were TV-positive, 37%
BV-positive, and 5% NG-positive;
806 incident TV infections (23.6
per 100 person-years) and 265
HIV seroconversions (7.7 per
100 person-years); multivariate
model with adjusted HR,
1.52 (95% CI, 1.04–2.24; P 5 .03)
for the association of TV infection
with HIV seroconversion; model
controlled for baseline education




duration of prostitution, no. of
partners per week, condom

























Study type citation Study design
Study population type and
setting Exposure and/or intervention Outcome measures Reported findings
Van der Pol 2008 Nested case-control
study (N 5 218 cases;
N 5 419 controls)
Women enrolled in longitudinal
cohort study of hormonal
contraception and HIV
acquisition in Uganda and
Zimbabwe
Women with incident HIV infection
(63 in Uganda; 155 in Zimbabwe)
classified as cases; controls matched
on study site on age, composite STI
variable (CT, NG, or BV), and length
of follow-up; for cases, samples
analyzed from seroconversion visit
and visit preceding seroconversion;
for controls, samples analyzed based
on follow-up closest to follow-up for
visits for cases; composite behavioral
risk variable used and primary sex
partner risk composite score used;
TV status based on microscopy
from parent study and PCR analysis




Median age, 24 years (cases
and controls); in multivariable
analysis, TV infection
associated with incident HIV
infection (adjusted OR, 2.74;
95% CI, 1.25–6.00); this risk
was higher after analyses
limited to lower-risk setting
(family planning participants)
with adjusted OR of 3.3
(95% CI, 1.36–7.85);
relationships even stronger
if analyses limited to positive
wet preparations only
(ie, eliminating those positive
only through PCR)
Impact of HIV on TV
acquisition and
clearance
Cu-Uvin 2002 Multicenter longitudinal
cohort study (N 5 871
HIV-positive women;
N 5 439 HIV-negative
women)
Women with HIV and women
at high risk of HIV acquisition
recruited from April 1993
through January 1995; women
with AIDS-defining illness
excluded
Every 6 months patients evaluated
with interview, examination, and
blood, urine, and genital tract
specimen collection; TV assessed
by wet preparation and TV culture
on visits 4–12
Analysis of data
from first 12 visits
Majority of patients black;
imputed TV infection
prevalence among HIV-positive
women, 29% vs 23% for
HIV-negative women; patients
with CD4 cell count of
,200 cells/lL less likely to
have baseline TV infection
(P 5 .03); on multivariate
analysis, baseline TV infection
associated with IDU, crack
cocaine use, ETOH, candidiasis,
and BV; black race, recent crack
cocaine use, cigarette use,
and BV associated with TV
infection in time trend; no
significant difference in
incidence, persistence, or


























Study type citation Study design
Study population type and
setting Exposure and/or intervention Outcome measures Reported findings
Magnus 2003 Retrospective cohort





aged .13 years with
at least 1 year
data available
Screened every 6 months by wet
preparation and CT antigen test or
ELISA for GC symptoms or urine
syphilis test and examination for
HPV; TV infection treated with
metronidazole (2 g or 500 mg twice
a day for 7 days); partners referred
for treatment
TV infection and risk
factors in HIV-positive
women
13.1% of women were
TV-positive, 5.3% CT-positive,
and 4.9% NG-positive; 30% of
1578 women had TV infection
at least 1 time; 37% had at least
1 subsequent positive test;
women ,22 years old, black,
with other STD, and substance
users had significantly higher
incidences of initial TV infection;
subsequent positive TV test
significantly higher in women
with any other STD; immune
status, ART use, and PI use
not associated with TV infection
Moodley 2003 Cross-sectional
study (N 5 692)
Women presenting to primary
health clinic in Kwa Zulu-Natal
with GU symptoms
Interview and examination;
TV infection diagnosis by culture;
syndromic symptoms treated
with cipro (250 mg orally once),
metronidazole (2 g once), and doxy
(200 mg a day for 7 days); return





Mean age, 24 years; vaginal
discharge present in 91% of
participants; 75% positive for
any STD; 29% had TV infection
(33% of HIV-positive women
and 25% of HIV-negative
women; P 5 .02); 80% of
women returned for follow-up
and 70% allowed another
examination; 65% of women
had TV infection clinically
cured and 88% microbiologically
cured; no difference in cure
rate by HIV status (90%
HIV-positive and 82%
HIV-negative women
cured; P 5 .3)
Abbreviations: ART, antiretroviral therapy; BV, bacterial vaginosis; CA, Candida albicans; CI, confidence interval; CSW, commercial sex worker; CT, Chlamydia trachomatis; ELISA, enzyme-linked immunosorbent assay;
FSW, female sex worker; GEE, generalized estimating equation; GU, genitourinary; GUD, genital ulcer disease; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, hazard ratio; IDU, injection drug use;
























60 HIV-positive women with trichomoniasis, 11 (18.3%) were
positive by TV culture 1 month after treatment with 2-gram
single-dose metronidazole therapy, including 6 (10.0%) who
were considered to have probable treatment failure. Among 301
HIV-negative women with trichomoniasis who were recruited
from family planning clinics, 24 (8.0%) were positive at 1 month
after treatment, including 22 (7.3%) who were considered to
have probable treatment failure. There was no significant dif-
ference in drug resistance between isolates from HIV-positive
women and those from HIV-negative women (3.3%), and the
majority of individuals responded to higher doses of metroni-
dazole (ie, 500 milligrams twice daily for 7–10 days). Similarly, in
a study involving in vitro susceptibility testing of TV isolates,
Schwebke and colleagues found that in vitro resistance was
poorly correlated with clinical response to treatment, a finding
that potentially implicates poor metronidazole efficacy in several
of the treatment failures documented in this study [73].
The argument for retesting young women diagnosed with
trichomoniasis after treatment can be based on the observation of
high recurrence rates. Peterman et al [71] studied 119 sexually
active women 15–39 years of age with TV infections recruited
from 3 public STD clinics. In this population, 16.5%were culture-
positive after 3 months, 18.5% were culture-positive after
6 months, and 12.5% were culture-positive after 9 months. A new
TV infection was more likely for women with initial diagnoses of
TV infection (16.5%) or gonococcal infection (14.8%). Because all
infections were initially treated with standard single-dose therapy,
we suggest that some TV infections may have been treatment
failures or reflect lack of partner treatment. Observations such as
those above highlight the need for additional research on the
prevalence and significance of persistent infection.
As discussed above, high rates of persistent and/or recurrent
trichomoniasis, although often difficult to sort out from re-
infection, raise concerns about treatment failure. Regardless of
the sex of the study participant, the choice of diagnostic test used
to document parasite eradication in treatment studies is partic-
ularly pertinent in terms of determination of treatment efficacy.
As mentioned above, wet preparation, the primary methodol-
ogy available for the majority of trichomonas treatment study
protocols performed in the past, is less sensitive than culture
and dramatically less sensitive than newer nucleic acid ampli-
fication tests. In fact, it is possible that utilization of wet
preparation for test of cure may have led to erroneously high
TV eradication rates due to false negative results in the earlier
treatment studies, an issue that raises concerns about the true
treatment efficacy of metronidazole. Future treatment studies
designed to address this issue should use newer, more sensitive
diagnostic tests in order to document organism eradication.
Whether the high TV recurrence rates are due to reinfection or
treatment failure, they argue that rescreening individuals with
documented TV infection following therapy may be considered.
CONCLUSION
Trichomoniasis is an extremely common, often asymptomatic,
STI that has been associated with potentially serious sequelae.
Advances in TV diagnosis have led to a greater appreciation of
the burden of trichomoniasis in the general population and the
biological and epidemiological interactions between TV and
HIV. Effective alternatives to the 5-nitroimidazole drugs are
needed for patients with drug allergy and nitroimidazole-
resistant TV infections. Optimal treatment regimens in men and
women require additional evaluation using newer diagnostic
tests to define therapeutic endpoints. Clinicians may consider
screening in those at high risk of infection. Emerging data
demonstrating the high prevalence of TV infection in the general
population and interactions between TV and HIV suggest that
additional research efforts should be directed at determining the
possible benefits of enhanced screening (optimal population and
intervals) for this important pathogen.
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